share_log

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Invivyd, Inc. F/k/a Adagio Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 3, 2023 - (IVVD)

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Invivyd, Inc. F/k/a Adagio Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 3, 2023 - (IVVD)

股東警報:總律師事務所通知 Invivyd,Inc. F/K/A Adaagio 治療,Inc. 的股東集體訴訟和主要原告截止日期為 2023 年 4 月 3 日-(IVVD)
newsfile ·  2023/02/07 18:40

New York, New York--(Newsfile Corp. - February 7, 2023) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (NASDAQ: IVVD).

紐約,紐約--(Newsfile Corp.-2023年2月7日)-格羅斯律師事務所證券訴訟律師事務所代表以下股東發佈以下通知Invivyd,Inc.f/k/a Adagio治療公司(納斯達克:IVVD)。

Shareholders who purchased shares of IVVD during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

鼓勵在所列類別期間購買IVVD股票的股東就可能任命首席原告一事與公司聯繫。被任命為首席原告不需要參與任何追償。

CONTACT US HERE:

請在此處聯繫我們:

This lawsuit is on behalf of all purchasers of Adagio common stock between November 29, 2021 and December 14, 2021, both dates inclusive.

這起訴訟是代表2021年11月29日至2021年12月14日期間(包括首尾兩天)購買Adagio普通股的所有買家。

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (a) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim that ADG20, an investigational monoclonal antibody treatment for COVID-19, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (b) defendants' claims regarding ADG20's efficacy against Omicron lacked a reasonable factual basis; and (c) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.

指控:起訴書稱,在上課期間,被告發表了具有重大虛假和/或誤導性的陳述和/或誤導性陳述,和/或未能披露:(A)已發表的表位映射、結構研究和序列分析表明,被告用來聲稱針對新冠肺炎的研究性單抗治療藥物對奧密克戎有效的表位映射、結構研究和序列分析不充分、不可靠,也不足以聲稱抗癌藥物對奧密克戎有效;(B)被告關於抗炎藥物對奧密克戎有效的說法缺乏合理的事實依據;及(C)抗炎藥物集團對奧密克戎變體的有效性是其針對先前變體的有效性的300多倍。

DEADLINE: April 3, 2023 Shareholders should not delay in registering for this class action. Register your information here:

截止日期:2023年4月3日股東不應拖延登記參加這起集體訴訟。在此處註冊您的資訊:

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of IVVD during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 3, 2023. There is no cost or obligation to you to participate in this case.

股東的下一步行動:一旦您登記為在上面列出的時間範圍內購買IVVD股票的股東,您將被登記在投資組合監控軟體中,以在案件的整個生命週期中為您提供狀態更新。尋求成為主要原告的最後期限是2023年4月3日。參與此案對您沒有任何成本或義務。

WHY GROSS LAW FIRM? The Gross Law Firm is nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

為什麼是格羅斯律師事務所?格羅斯律師事務所是全國公認的集體訴訟律師事務所,我們的使命是保護所有因欺詐、欺詐和非法商業行為而蒙受損失的投資者的權利。格羅斯律師事務所致力於確保公司遵守負責任的商業實踐,並從事良好的企業公民行為。當一家公司的虛假和/或誤導性陳述或重大資訊遺漏導致該公司股票人為膨脹時,該公司代表遭受損失的投資者尋求賠償。律師廣告。以前的結果並不能保證類似的結果。

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

格羅斯律師事務所致力於確保公司遵守負責任的商業實踐,並從事良好的企業公民行為。當一家公司的虛假和/或誤導性陳述或重大資訊遺漏導致該公司股票人為膨脹時,該公司代表遭受損失的投資者尋求賠償。律師廣告。以前的結果並不能保證類似的結果。

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

聯繫方式:
格羅斯律師事務所
西38街15號,12樓
紐約,紐約州,10018
電子郵件:dg@securitiesclasslaw.com
電話:(212)537-9430
傳真:(833)862-7770

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論